Partners HealthCare has co-led a series A round for ZielBio to drive forward the development of a cancer treatment based on research at University of Virginia.
US-based biotechnology developer ZielBio closed a $25.1m series A round on Thursday co-led by Partners Innovation Fund (PIF), the investment arm of health system Partners HealthCare, and Morningside Venture Investments.
Founded in 2012 as iTiHealth, ZielBio has built a platform called Zielfind that combines functional, high-throughput screening with data analytics to identify high-value targets for therapeutics.
The company is initially focusing on ZB131, an antibody against cell surface plectin (CSP), a target highly expressed in several indications of cancer, including…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
